How Do You Solve A Problem Like Biopsy In Alcohol-Associated Liver Disease?
Executive Summary
Biopsy results may be informative in early phase trials, but costs have limited their use in US clinical practice, raising questions about whether procedure should be required in drug development.
You may also be interested in...
Deleting The 'Alcohol' From Alcoholic Liver Disease
Alcoholism is not a requirement to develop condition, but often is assumed of patients, so researchers offer name change to avoid stereotypes.
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.
Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
Emails reveal company wanted timelines and approval commitments from FDA toward the end of the eteplirsen review, saying it might not be able to continue studies; at the same time, Sarepta was telling investors it had 12 months of cash on hand.